PLANTATION, Fla., Feb. 7 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced the appointment of Professor Nancy A. Speck,
Ph.D., to its Board of Directors. Dr. Speck is a distinguished professor and
researcher in the field of cancer at Dartmouth Medical School and holds the
James J. Carroll Chair in Oncology.
Widely published and a recipient of numerous honors and grants, Dr. Speck
received her B.A. degree from Western Maryland College (now McDaniel College)
in 1977, and her Ph.D. in immunology from Northwestern University in 1982.
She trained as a postdoctoral fellow at the Center for Cancer Research and the
Whitehead Institute at the Massachusetts Institute of Technology. Dr. Speck
moved to Dartmouth Medical School in 1989 as an Assistant Professor. She is
currently a Professor of Biochemistry, the Associate Director for Basic
Science at the Norris Cotton Cancer Center at Dartmouth, and holds the
prestigious James J. Carroll Chair in Oncology.
"Dr. Speck is an internationally recognized teacher, researcher and expert
in the field of cancer, and significantly strengthens our Board from a
scientific perspective," stated Viragen's Chairman, Mr. Carl N. Singer. "We
are pleased to add another highly qualified independent director and we look
forward to her objective insight and contributions as we continue to strive to
build stockholder value."
Commenting on her new role, Dr. Speck stated, "This is an exciting
opportunity for me as Viragen possesses a product portfolio with dramatic
potential to impact many lives in a positive way. I hope to help further the
Company's scientific and commercial goals and certainly look forward to
working with this accomplished and talented group."
Dr. Speck replaces Dr. Douglas Lind, who has resigned from Viragen's Board
to form a healthcare investment fund. Mr. Singer commended Dr. Lind for his
contributions: "We have benefited from Dr. Lind's involvement and we wish him
well in his new endeavor."
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
